<h4>Objective</h4>This study aims to evaluate the oncological outcomes, functional recovery and overall satisfaction following cytoreductive radical prostatectomy (CRP) in patients with oligometastatic prostate cancer treated at a single tertiary-care centre.<h4>Patients and methods</h4>Between 2021 and 2024, 12 patients with clinically and radiologically confirmed oligometastatic prostate cancer (≤5 bone lesions, no visceral metastases) underwent open retropubic CRP after 6 months of neoadjuvant androgen deprivation therapy (ADT) and targeted radiotherapy to metastatic sites. The gene discussed is CRP; the disease is prostate cancer.